MacroGenics, Inc. (MGNX) News
Filter MGNX News Items
MGNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MGNX News Highlights
- For MGNX, its 30 day story count is now at 2.
- Over the past 5 days, the trend for MGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest MGNX News From Around the Web
Below are the latest news stories about MACROGENICS INC that investors may wish to consider to help them evaluate MGNX as an investment opportunity.
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years agoIt is a pleasure to report that the MacroGenics, Inc. ( NASDAQ:MGNX ) is up 74% in the last quarter. But that doesn't... |
Q3 2023 MacroGenics Inc Earnings CallQ3 2023 MacroGenics Inc Earnings Call |
MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call TranscriptMacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good afternoon. We will begin the MacroGenics 2023 Third Quarter Corporate Progress and Financial Results Conference Call in just a moment. [Operator Instructions] At this point, I will turn the call over to Jim Karrels, Senior Vice President and Chief Financial Officer of […] |
MacroGenics (MGNX) Q3 2023 Earnings Call TranscriptAt this point, I will turn the call over to Jim Karrels, senior vice president and chief financial officer of MacroGenics. Good afternoon and welcome to MacroGenics conference call to discuss our third quarter 2023 financial and operational results. |
Macrogenics Inc (MGNX) Reports Q3 2023 Earnings: Net Income of $17. ...Company's Cash Position Increases to $256.4 Million, Up from $154.3 Million at the End of 2022 |
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial ResultsCompleted enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an updat |
MacroGenics to Participate in Upcoming Investor ConferencesROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: BMO Biopharma Spotlight Series: Oncology Day Date: Wednesday, November 8, 2023 Fireside Chat: 10:30 am ET Location: VirtualStifel 2023 Healthcare Confere |
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference CallROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, |
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research ProgramROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upo |